Cancer: Pathophysiology, Current Therapies, Clinical Trials, and Drug Development

Cancer: Pathophysiology, Current Therapies, Clinical Trials, and Drug Development

PERI’s comprehensive three-day oncology course reviews current and emerging drugs, immunotherapies, their application to specific cancer types, how to conduct clinical trials for oncologic therapies, and the drug development process for drug candidates leading to their approval. The US Food & and Drug Administration (FDA) regulatory considerations for Oncology drugs, registration endpoints, and accelerated and breakthrough approval mechanisms are also covered. This course is ideal for individuals transitioning into the oncology field to explore a variety of cancer types, as well as fundamental components of developing therapies for cancer, including nonclinical development, toxicology, dosing, clinical trial design, and regulatory considerations. New this fall: post-marketing drug safety and medical affairs!

  • Provider:Pharmaceutical Education & Research Institute
  • Activity Link: https://peri.org/open-courses/cancer-october-2024/
  • Start Date: 2025-10-23 05:00:00
  • End Date: 2025-10-23 05:00:00
  • Credit Details: AMA PRA Category 1 Credit™️: 12.25 hours
  • Commercial Support: Source: AstraZeneca (Any division) - Amount: 0 - Is Kind Support: False
  • Activity Type: Live Course
  • CME Finder Type: Conference
  • Fee to Participate: Yes
  • Measured Outcome: Learner Competence, Learner Knowledge
  • Provider Ship: Directly Provided
  • Registration: Open to all
«
»
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x

Contact us

If you want to join leaders who will shape what Americans think about sleep.

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.

Sign up for the expert list

for media inquiries

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.